A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

AZ later said that it believes Chinese authorities are looking into whether the company’s employees had illegally imported ...

Buoyed by the success of Enhertu (trastuzumab deruxtecan) in HER2-positive and HER2-low cancers - Daiichi Sankyo expects it to make around $1.3 billion this fiscal year - AZ shelled out $1 billion ...

contributing significantly to the market's commercial success. Two key players in this domain are the aforementioned Kadcyla and Enhertu, both of which have demonstrated remarkable efficacy and have ...

Modular Devices is excited to announce the addition of David Frank as Fractional Chief Commercial Officer, reinforcing the company's commitment to strategic growth and leadership within the cleanroom ...

Sales Focus Inc. (SFI), a leading provider of outsourced sales solutions, was awarded Best Global B2B Outsourced Sales Services Provider in 2024 by ...

Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe into alleged breaches of laws around drug importation and data privacy, the ...

Enhertu’s first-mover advantage and overall brand equity ... We’ll need to watch for its success (and possible challenges) in testing for patients who express NRG1. The pending approval will also add ...